QC
SMMT icon

Quent Capital’s Summit Therapeutics SMMT Stock Holding History

Quent Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99K Buy
+105
New +$1.7K ﹤0.01% 1392
2025
Q4 		– Sell
-51
Closed -$1.05K – 1611
2025
Q3 		$1.05K Buy
+51
New +$1.24K ﹤0.01% 1320

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quent Capital's SMMT Position: Q1 2026 in Review

Quent Capital opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 105 shares worth $1.99K. The stake represents ﹤0.01% of the portfolio and ranks #1392 among its holdings. This is a return to the name: Quent Capital previously reported a position in SMMT as recently as Q3 2025.

Quent Capital first reported a position in SMMT in Q3 2025 and has held it in 2 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Quent Capital held 105 shares of Summit Therapeutics worth $1.99K as of Q1 2026.
  • Summit Therapeutics was a new Quent Capital position in Q1 2026.
  • Summit Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q1 2026, its #1392 holding.
  • Quent Capital first reported a position in Summit Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.